Prelude Therapeutics develops precision cancer medicines, including targeted protein degraders and antibody drug conjugates, for patients with underserved cancers. PRLD reports earnings on Wed, Nov 11, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 17 | JP Morgan | Initiated | Buy | |
| Jul 29 | HC Wainwright & Co. | Reiterated | Buy | |
| May 4 | D. Boral Capital | Initiated | Buy |
Seasonality
How PRLD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in PRLD in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PRLD is in one of them and how their past PRLD trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PRLD in an article yet. Here's the latest on the wider market.
About Prelude Therapeutics
Prelude Therapeutics is a precision oncology company based in Wilmington, Delaware. It discovers and develops cancer medicines, including small molecule inhibitors, protein degraders, and antibody drug conjugates, aimed at cancers with limited treatment options. Its pipeline targets driver mutations in blood cancers and solid tumors, such as a JAK2V617F inhibitor for myeloproliferative neoplasms and a KAT6A degrader for advanced breast cancer. The company serves cancer patients and is advancing its candidates through clinical trials.
- Headquarters
- Wilmington, DE